Manny Pacquiao net worth: How much money boxing legend has made in career earnings, endorsements and politics
A legendary boxer who took on a political career and even dabbled in professional basketball, Pacquiao is now one of the faces of the Philippines — and money is no longer an issue. Between winnings and endorsement deals, Pacquiao has amassed more wealth than he ever could have imagined.
Here's a closer look at Pacquiao's net worth, career earnings and sponsorship deals.
MORE:Ranking Manny Pacquiao's 9 best fights
Manny Pacquiao net worth
Pacquiao has an estimated net worth of $220 million, according to Celebrity Net Worth. For someone whose family struggled so much financially while he was growing up, that is a remarkable figure.
Pacquiao has earned plenty of winnings in his boxing career, which includes 62 wins and numerous high-profile fights, but he has also made significant money through endorsement deals as a result of his global popularity.
MORE:What happened when Manny Pacquiao fought Floyd Mayweather?
Manny Pacquiao career earnings in boxing
Pacquiao has made $575 million in career earnings as a boxer — or $775 million adjusted for inflation. Pacquiao's non-adjusted figure ranks third among fighters behind only Floyd Mayweather and Mike Tyson.
Pacquiao's pay-per-view fights have generated nearly $1.3 billion in revenue, including a stunning $400 million for his highly-publicized fight against Mayweather in 2015. While he certainly doesn't see all of that revenue, he sees enough — and won enough in other fights — to amass hundreds of millions in earnings.
In 2012, Forbes ranked Pacquiao as the second highest-earning athlete of the year, trailing only Mayweather.
MORE:Boxing scoring, explained: A guide to understanding the rules, points system and judges
Manny Pacquiao endorsements
Like many prominent athletes, Pacquiao has acquired plenty of his wealth through brand endorsement deals. At the height of his career, Pacquiao had deals with Nike, Nestle, Hewlett-Packard and Hennessy, according to the Intellectual Property Office of the Philippines. Very few details of the deals were disclosed, though it was reported Pacquiao's deal with HP was worth more than $1 million.
Pacquiao's other sponsorship deals included Wonder Pistachios, Monster Energy, Sony and San Miguel Beer, though his brand started to suffer a bit when he suffered back-to-back losses in 2012.
In 2016, Nike dropped Pacquiao over controversial comments he made criticizing same-sex relationships. Pacquiao issued an apology for the words he chose but not the sentiment, and he signed a new deal with Chinese apparel brand Anta later in the year.
MORE:Meet Manny Pacquiao's aspiring boxer son, politician wife and more
Manny Pacquiao career earnings in politics
Pacquiao's positions in the Filipino government did not come with high-paying salaries. While the exact figures he received year-by-year are not available, even the president of the Philippines — an office he unsuccessfully sought in 2022 — makes less than $100,000 per year in U.S. dollars.
Compared to the money Pacquiao made as a boxer and through endorsement deals, his foray into politics was not lucrative on its own.
MORE:Manny Pacquiao politics timeline, from becoming a senator to a run for President
Manny Pacquiao career earnings in music, acting and media
Pacquiao has made a handful of TV and movie appearances in his career, including acting roles in Filipino films early in his boxing career. More recently, most of his appearances have been as himself — including numerous appearances in documentaries.
There is no available information regarding Pacquiao's earnings from acting or media appearances, though his appearances largely haven't been significant enough to assume a notable chunk of his net worth comes from the screen.
Tax issues and legal settlements
Pacquiao and his wife were assessed a $55.8 million tax bill, including penalties and interest, for allegedly failing to completely pay what he owed between 2008 and 2009, taking issue with his failure to report U.S. earnings. Pacquiao claimed he paid the taxes in the U.S.
However, an appeals court dismissed the bill in 2022, ruling that the tax agency violated Pacquiao's due process by basing the assessment on news reports and not informing him of the the factual basis behind the assessment.
While Pacquiao has a net worth of more than $220 million today, a $55.8 million tax payment would have been a significant hit for the legendary boxer. "I thank the Lord that the truth has come out," Pacquiao said after the ruling, which was upheld in early 2025.
MORE:Why Mario Barrios said 'the respect won't be there' when he fights Manny Pacquiao
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
BEIJING, July 28, 2025--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the "BioMice" sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice® platforms—including RenMab™ (fully human antibody), RenLite® (common light chain), RenNano® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Contacts Biocytogen Contacts Preclinical Products and Services: info@ Antibody assets and platforms: BD-Licensing@ Media: pr@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
New York Post
42 minutes ago
- New York Post
Stocks surge, euro steady after US-EU trade agreement
Global stocks rose and the euro appreciated on Monday after a trade agreement between the United States and the EU lifted sentiment and provided some clarity in a week of key policy meetings by the Federal Reserve and the Bank of Japan. The US struck a framework trade agreement with the European Union, imposing a 15% import tariff on most EU goods – half the threatened rate, a week after agreeing to a similar trade deal with Japan. Countries are scrambling to finalise trade deals ahead of an August 1 deadline set by US President Donald Trump, with talks between the US and China set for Monday in Stockholm amid expectations of another 90-day extension to the truce between the world's top two economies. 3 President Donald Trump (R) shakes hands with European Commission President Ursula von der Leyen (L) following their meeting, in Turnberry, south west Scotland on July 27, 2025. AFP via Getty Images 'A 15% tariff on European goods, forced purchases of US energy and military equipment and zero tariff retaliation by Europe, that's not negotiation, that's the art of the deal,' said Prashant Newnaha, senior Asia-Pacific rates strategist at TD Securities. 'A big win for the US.' European futures surged more than 1%, while S&P 500 futures rose 0.5% and Nasdaq futures advanced 0.6%. The euro strengthened across the board, rising against the dollar, sterling and yen. 'We have to be a bit cautious from here,' said Sim Moh Siong, currency strategist at Bank of Singapore, of the broader risk-on rally. 'A lot of good news is already in the price.' MSCI's broadest index of Asia-Pacific shares outside Japan was up 0.32%, just shy of the almost four-year high it touched last week. Japan's Nikkei fell 1% after hitting a one-year high last week. While the baseline 15% tariff will still be seen by many in Europe as too high, compared with Europe's initial hopes to secure a zero-for-zero tariff deal, it is better than the threatened 30% rate. 3 Currency traders work near a screen showing the Korea Composite Stock Price Index (KOSPI) and the foreign exchange rate between US dollar and South Korean won, right, at the foreign exchange dealing room of the Hana Bank headquarters in Seoul, South Korea, Monday, July 28, 2025. AP The US-EU deal provides clarity to companies and averts a bigger trade war between the two allies that account for almost a third of global trade. 'A major tail-risk has now been defused,' said Marc Velan, head of investments at Lucerne Asset Management in Singapore. 'Markets are interpreting this as a sign of stability and predictability returning to trade policy,' he added. 'The China delay fits the same pattern: the administration is opting for controlled diplomacy over confrontation.' 3 The US struck a framework trade agreement with the European Union, imposing a 15% import tariff on most EU goods – half the threatened rate, a week after agreeing to a similar trade deal with Japan. AP Gains for China's blue-chip stocks petered out towards the midday break, while Hong Kong's Hang Seng index gained 0.5%. The Australian dollar , often seen as a proxy for risk appetite, was at $0.657, hovering around the near eight-month peak scaled last week. FED, BOJ AWAIT In an action-packed week, investors will watch out for the monetary policy meetings from the Fed and the BOJ as well as the monthly US employment report and earnings from megacap companies Apple, Microsoft and Amazon. While the Fed and the BOJ are expected to maintain rates, comments from the officials will be crucial for investors to gauge the interest rate path. The trade deal with Japan has opened the door for the BOJ to raise rates again this year. Meanwhile, the Fed is likely to be cautious on any rate cuts as officials seek more data to determine tariffs' impact on inflation before they ease rates further. But tensions between the White House and the central bank over monetary policy have increased, with Trump repeatedly lashing out at Fed Chair Jerome Powell for not cutting rates. Two of the Fed Board's Trump appointees have articulated reasons for supporting a rate cut this month. In commodities, oil prices rose after the US-EU trade agreement. Brent crude futures and US West Texas Intermediate crude both rose 0.5%. Gold prices fell on Monday to their lowest in nearly two weeks on reduced appetite for safe havens.
Entrepreneur
42 minutes ago
- Entrepreneur
Defence Tech Startup Ammunic Systems Bags USD 1.1 Mn Funding
The funding will be deployed to boost research and development, scale manufacturing, expand the team, and enhance new and existing product lines focused on indigenous defence technology. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Ammunic Systems has raised USD 1.1 million in a seed funding round co-led by India Accelerator and Finvolve. The funding will be deployed to boost research and development, scale manufacturing, expand the team, and enhance new and existing product lines focused on indigenous defence technology. The capital infusion is set to support Ammunic Systems' ambition of accelerating its innovation roadmap and advancing India's self-reliance in strategic defence solutions. With a strong emphasis on cutting-edge technologies, the startup is positioning itself as a key player in modern warfare systems. "This investment from India Accelerator is not just capital; it is a vote of confidence in a mission we have poured our hearts into. At Ammunic Systems, we are not just building defence technologies; we are building belief — that India can lead from the front in securing its own future," said Priyanka Singhal, Founder of Ammunic Systems. Founded in 2024, Ammunic Systems is headquartered in Bengaluru. The company specialises in the research and development of advanced weapon systems. Its core expertise lies in electronic fuzes, warheads, and munition integration technologies. These products aim to offer precision, safety, and efficiency for current and future defence needs. Ammunic Systems provides end-to-end solutions across the defence product cycle — from concept design and testing to full-scale production. The startup aspires to become a leading innovator in the defence and aerospace sector by focusing on indigenous manufacturing and next-generation technologies. The investment community views such ventures as crucial to reducing India's dependency on defence imports. "India is at a critical point in its defence evolution, which makes indigenous technological capabilities national priorities. Ammunic Systems exemplifies the deep-tech innovation needed to strengthen our defence ecosystem," said Ashish Bhatia, Founder of India Accelerator and Co-founder of Finvolve.
